Bionano Genomics (BNGO) Operating Leases (2021 - 2026)

Bionano Genomics (BNGO) has 6 years of Operating Leases data on file, last reported at $2.5 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Leases changed N/A year-over-year to $2.5 million; the trailing twelve-month figure through Mar 2026 stood at $2.5 million (changed N/A YoY), and the FY2025 full-year result was $2.5 million, up 1616.55% from the prior year.
• Operating Leases advanced to $2.5 million in Q1 2026, from $2.5 million in the prior quarter.
• In the past five years, Operating Leases ranged from a high of $7.3 million in Q1 2023 to a low of $145000.0 in Q4 2024.
• A 5-year average of $4.1 million and a median of $4.2 million in 2024 frame the typical range for Operating Leases.
• Across the five-year window, Operating Leases tumbled 95.96% in 2024 and surged 1616.55% in 2025, its largest moves.
• Tracing BNGO's Operating Leases over 5 years: stood at $5.5 million in 2022, then plunged by 34.77% to $3.6 million in 2023, then plunged by 95.96% to $145000.0 in 2024, then surged by 1616.55% to $2.5 million in 2025, then gained by 0.72% to $2.5 million in 2026.
• Business Quant data shows BNGO's Operating Leases at $2.5 million in Q1 2026, $2.5 million in Q4 2025, and $2.6 million in Q3 2025.